Aytu BioPharma (AYTU) 10-Q 11 Feb 16 2016 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Dec. 31, 2015	Feb. 01, 2016
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Dec. 31, 2015
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q2
Entity Registrant Name	AYTU BIOSCIENCE, INC
Entity Central Index Key	1,385,818
Current Fiscal Year End Date	--06-30
Entity Filer Category	Smaller Reporting Company
Trading Symbol	AYTU
Entity Common Stock, Shares Outstanding		14,567,385

Balance Sheets

Balance Sheets - USD ($)	Dec. 31, 2015	Jun. 30, 2015
Current assets
Cash and cash equivalents	$ 10,959,546	$ 7,353,061
Accounts receivable	288,466	157,058
Inventory	653,115	39,442
Prepaid expenses, other	741,544	370,888
Prepaid research and development - related party (Note 11)	121,983	121,983
Total current assets	12,764,654	8,042,432
Fixed assets, net (Note 2)	143,826	29,706
Developed technology, net	1,242,569	780,125
Customer contracts, net	1,456,875	711,000
Trade names, net	210,139	79,000
Goodwill	221,000	74,000
In-process research and development	7,500,000	7,500,000
Patents, net	593,382	628,776
Long-term portion of prepaid research and development - related party (Note 11)	274,463	335,454
Deposits	2,888	4,886
Total non current assets	11,645,142	10,142,947
Total assets	24,409,796	18,185,379
Current liabilities
Accounts payable and accrued liabilities	1,076,295	1,195,368
Primsol payable	1,111,057	0
Accrued compensation	492,584	196,503
Deferred revenue	85,714	85,714
Related party payable	38,451	0
Total current liabilities	2,804,101	1,477,585
Convertible promissory notes, net of amortization discount of $253,448 (Note 8)	4,921,552	0
Contingent consideration	687,685	664,000
Long-term deferred revenue	383,036	425,893
Interest payable	161,988	0
Deferred rent	11,694	1,449
Warrant derivative liability	180,969	0
Total liabilities	$ 9,151,025	$ 2,568,927
Commitments and contingencies (Note 7)
Stockholders' equity
Preferred Stock, par value $.0001; 50,000,000 shares authorized; none issued	$ 0	$ 0
Common Stock, par value $.0001; 300,000,000 shares authorized; shares issued and outstanding 14,259,693 and 14,259,681, respectively as of December 31, 2015 and June 30, 2015	1,426	1,426
Additional paid-in capital	39,247,254	38,996,367
Ampio stock subscription	0	(5,000,000)
Accumulated deficit	(23,989,909)	(18,381,341)
Total stockholders' equity	15,258,771	15,616,452
Total liabilities and stockholders' equity	$ 24,409,796	$ 18,185,379

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical) - USD ($)	Dec. 31, 2015	Jun. 30, 2015
Convertible promissory notes, amortization discount	$ 253,448	$ 253,448
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, authorized shares	50,000,000	50,000,000
Preferred stock, issued shares	0	0
Common Stock, par value	$ 0.0001	$ 0.0001
Common stock, authorized shares	300,000,000	300,000,000
Common stock, issued shares	14,259,693	14,259,681
Common stock, outstanding shares	14,259,693	14,259,681

Statements of Operations

Statements of Operations - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2015	Dec. 31, 2014
Product and service revenue	$ 447,786	$ 6,906	$ 913,742	$ 13,060
License revenue	21,428	21,429	42,857	42,858
Total revenue	469,214	28,335	956,599	55,918
Operating expenses
Cost of sales	244,100	0	281,425	225
Research and development	1,308,460	789,967	2,164,334	1,723,720
Research and development - related party (Note 11)	47,998	53,998	95,996	107,996
Sales, general and administrative	1,774,167	749,837	3,425,971	1,863,416
Amortization of finite-lived intangible assets	108,489	17,697	165,936	35,394
Total operating expenses	3,483,214	1,611,499	6,133,662	3,730,751
Loss from operations	(3,014,000)	(1,583,164)	(5,177,063)	(3,674,833)
Other (expense) income
Interest (expense)	(240,214)	(37,547)	(353,467)	(74,849)
Derivative (expense)	(78,166)	0	(78,038)	0
Total other (expense) income	(318,380)	(37,547)	(431,505)	(74,849)
Net loss, before income tax	(3,332,380)	(1,620,711)	(5,608,568)	(3,749,682)
Deferred income tax benefit	0	0	0	23,910
Net loss	$ (3,332,380)	$ (1,620,711)	$ (5,608,568)	$ (3,725,772)
Weighted average number of Aytu common shares outstanding	14,259,693	7,901,426	14,259,687	7,901,426
Basic and diluted Aytu net loss per common share	$ (0.23)	$ (0.21)	$ (0.39)	$ (0.47)

Statement of Stockholders' Equi

Statement of Stockholders' Equity - 6 months ended Dec. 31, 2015 - USD ($)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Ampio Stock Subscription [Member]	Accumulated Deficit [Member]
Balance at Jun. 30, 2015	$ 15,616,452	$ 1,426	$ 38,996,367	$ (5,000,000)	$ (18,381,341)
Balance (in shares) at Jun. 30, 2015		14,259,681
Adjustment for rounding of shares due to conversion	0	$ 0	0	0	0
Adjustment for rounding of shares due to conversion (in shares)		12
Ampio stock subscription	5,000,000	$ 0	0	5,000,000	0
Stock-based compensation	250,887	$ 0	250,887	0	0
Stock-based compensation (in shares)		0
Net loss	(5,608,568)	$ 0	0	0	(5,608,568)
Balance at Dec. 31, 2015	$ 15,258,771	$ 1,426	$ 39,247,254	$ 0	$ (23,989,909)
Balance (in shares) at Dec. 31, 2015		14,259,693

Statements of Cash Flows

Statements of Cash Flows - USD ($)	6 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Cash flows from operating activities
Net loss	$ (5,608,568)	$ (3,725,772)
Stock-based compensation expense	250,887	477,660
Depreciation, amortization and accretion	242,427	49,164
Amoritzation of debt issuance costs	147,805	0
Derivative expense	78,038	0
Amortization of prepaid research and development - related party (Note 11)	60,991	60,992
Deferred taxes	0	(23,910)
Adjustments to reconcile net loss to net cash used in operating activities:
(Increase) in accounts receivable	(131,408)	(6,906)
(Increase) in inventory	(613,673)	(10,453)
(Increase) decrease in prepaid expenses, other	(370,656)	485,889
(Increase) in prepaid research and development - related party (Note 11)	0	(150,000)
(Decrease) in accounts payable and accrued liabilities	(126,781)	(298,677)
Increase (decrease) in related party payable	38,451	(561,059)
Increase in accrued compensation	296,081	94,247
Increase in interest payable	161,988	74,936
Increase in deferred rent	10,245	0
(Decrease) in deferred revenue	(42,857)	(42,858)
Net cash used in operating activities	(5,607,030)	(3,576,747)
Cash flows used in investing activities
Deposits	1,998	(1,998)
Purchases of fixed assets	(125,161)	0
Purchase of Primsol business	(540,000)	0
Net cash used in investing activities	(663,163)	(1,998)
Cash flows from financing activities
Proceeds from convertible promissory notes, net (Note 8)	5,175,000	0
Debt issuance costs (Note 8)	(298,322)
Ampio stock subscription payment	5,000,000	0
Contribution from Ampio	0	1,100,000
Net cash provided by financing activities	9,876,678	1,100,000
Net change in cash and cash equivalents	3,606,485	(2,478,745)
Cash and cash equivalents at beginning of period	7,353,061	2,639,650
Cash and cash equivalents at end of period	10,959,546	160,905
Non-cash transactions:
Warrant derivative liability related to the issuance of the convertible promissory notes (Note 8)	102,931	0
Primsol business purchase included in primsol payable, $1,250,000 less future accretion of $173,000	1,077,000	0
Fixed asset purchases included in accounts payable	$ 7,708	$ 0

Statements of Cash Flows (Paren

Statements of Cash Flows (Parenthetical) - USD ($)	6 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Primsol Business Purchase Included In Primsol Payable Gross	$ 1,250,000	$ 1,250,000
Accretion of Discount	$ 173,000	$ 173,000

Business, Acquisition of Assets

Business, Acquisition of Assets and Basis of Presentation	6 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Business Description and Basis of Presentation [Text Block]	Note 1 – Business, Acquisition of Assets and Basis of Presentation Business/Acquisition of Assets Aytu BioScience, Inc. (“Aytu” or the “Company”) was incorporated as Rosewind Corporation on August 9, 2002 in the State of Colorado. Aytu was re-incorporated in the state of Delaware on June 8, 2015. Aytu is a specialty healthcare company concentrating on acquiring, developing and commercializing products focused primarily on the urological disorders market, specifically sexual dysfunction, urological cancer, urinary tract infections and male infertility. These unaudited financial statements represent the financial statements of Aytu BioScience, Inc. (“Aytu” or “the Company”). These unaudited financial statements should be read in conjunction with Aytu’s Annual Report on Form 10-K for the year ended June 30, 2015, which included all disclosures required by generally accepted accounting principles (“GAAP”). In the opinion of management, these unaudited financial statements contain all adjustments necessary to present fairly the financial position of Aytu for the balance sheet and the results of operations and cash flows for the interim periods presented. The results of operations for the period ended December 31, 2015 are not necessarily indicative of expected operating results for the full year. The information presented throughout this report as of and for the period ended December 31, 2015 is unaudited. Aytu’s current business was formed through a reverse triangular merger (the “Merger”) in which Luoxis Diagnostics, Inc. (“Luoxis”) and Vyrix Pharmaceuticals, Inc. (“Vyrix”) merged into Rosewind Corporation in a multi-step merger on April 16, 2015. These historical financial statements prior to April 16, 2015 include the combined financial statements of Vyrix from its inception in November 2013, combined with the carve-out financial statements related to Vyrix assets acquired in the Merger (the “Vyrix Acquired Assets”) from March 23, 2011, the date its parent company, Ampio Pharmaceuticals, Inc. (“Ampio”), originally acquired the Vyrix Acquired Assets through its merger with DMI BioSciences, Inc. (“BioSciences”) and the financial statements of Luoxis from its inception in January 2013, combined with the carve-out financial statements related to Luoxis. The carve-out financial statements present the statements of financial position of Vyrix and Luoxis and the Vyrix Acquired Assets and the statements of operations and cash flows for purposes of presenting complete comparative stand-alone financial statements in accordance with Regulation S-X, Article 3, General Instructions to Financial Statements, and Staff Accounting Bulletin Topic 1-B1, Costs Reflected in Historical Financial Statements. Historically, financial statements have not been prepared for Vyrix and Luoxis, as they were not held in a separate legal entity. Although Vyrix and Luoxis have not been segregated as a separate legal entity, related revenues, direct costs and expenses, assets and liabilities have historically been segregated on Ampio’s books. In addition, the Company allocated corporate overhead costs based on a review of specific labor and other overhead expenses and a reasonable estimate of activities related to Vyrix and Luoxis. Allocated labor and other overhead totaled $ 264,000 253,000 ically been funded by Ampio. The historical carve-out financial statements may not be indicative of the future results of Vyrix and Luoxis as a stand-alone entity. The “Company” as referred to in the notes to these financial statements includes Vyrix and Luoxis, collectively. As of December 31, 2015, Ampio is the majority shareholder of 81.5 12.174 In May 2015, Aytu entered into and closed on an asset purchase agreement with Jazz Pharmaceuticals, Inc. (the “Seller”). Pursuant to the agreement, Aytu purchased assets related to the Seller’s product known as ProstaScint® (capromab pendetide), including certain intellectual property and contracts, and the product approvals, inventory and work in progress (together, the “ProstaScint Business”), and assumed certain of the Seller’s liabilities, including those related to product approvals and the sale and marketing of ProstaScint. The purchase price consisted of the upfront payment of $ 1.0 500,000 227,000 8 2.5 664,000 2.4 Fair Tangible assets $ 727,000 Intangible assets 1,590,000 Goodwill 74,000 Total assets acquired $ 2,391,000 Included in the intangible assets is developed technology of $ 790,000 720,000 80,000 As of December 31, 2015 the contingent consideration had increased to $ 688,000 Business Combination—Primsol In October 2015, Aytu entered into and closed on an Asset Purchase Agreement with FSC Laboratories, Inc. (the “Seller”). Pursuant to the agreement, Aytu purchased assets related to the Seller’s product known as Primsol® (trimethoprim solution), including certain intellectual property and contracts, inventory, work in progress and all marketing and sales assets and materials related solely to Primsol (together, the “Primsol Business”), and assumed certain of the Seller’s liabilities, including those related to the sale and marketing of Primsol arising after the closing. Aytu paid $ 500,000 142,000 102,000 40,000 500,000 500,000 250,000 Fair Tangible assets $ 182,000 Intangible assets 1,470,000 Goodwill 147,000 Total assets acquired $ 1,799,000 Included in tangible assets is $ 102,000 80,000 520,000 810,000 140,000 In September 2015, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2015-16, “Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments,” which requires that an acquirer recognize adjustments to estimated amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined. The amendments require that the acquirer record, in the same period’s financial statements, the effect on earnings of changes in depreciation, amortization, or other income effects, if any, as a result of the change to the estimated amounts, calculated as if the accounting had been completed at the acquisition date. The amendments also require an entity to present separately on the face of the income statement or disclose in the notes the portion of the amount recorded in current-period earnings by line item that would have been recorded in previous reporting periods if the adjustment to the estimated amounts had been recognized as of the acquisition date. The amendment is effective for financial statements issued for fiscal years beginning after December 15, 2015 and early adoption is permitted. As of December 31, 2015, the Company has early adopted this standard. In April 2015, the FASB issued ASU 2015-03, “Interest-Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs” to simplify the presentation of debt issuance costs. The amendments in the update require that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct reduction of the carrying amount of the debt. Recognition and measurement of debt issuance costs were not affected by this amendment. In August 2015, FASB issued ASU 2015-15, “Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements — Amendments to SEC Paragraphs Pursuant to Staff Announcement at June 18, 2015 EITF Meeting” which clarified that the SEC would not object to an entity deferring and presenting debt issuance costs as an asset and subsequently amortizing the deferred debt issuance costs ratably over the term of the line-of-credit arrangement. The amendments are effective for financial statements issued for fiscal years beginning after December 15, 2015. As of December 31, 2015, the Company early adopted this standard and will record any debt issuance costs as a debt discount. There was no impact related to this adoption as the Company did not have any debt issuance costs previously. In November 2015, the FASB issued ASU No. 2015-17 regarding ASC Topic 470 "Income Taxes: Balance Sheet Classification of Deferred Taxes." The amendments in ASU 2015-17 eliminate the requirement to bifurcate deferred taxes between current and non-current on the balance sheet and requires that deferred tax liabilities and assets be classified as noncurrent on the balance sheet. The amendments for ASU-2015-17 can be applied retrospectively or prospectively and early adoption is permitted. Aytu early adopted ASU 2015-17 and there was no material impact on its financial statements. Recently Issued Accounting Pronouncements, Not Adopted as of December 31, 2015 In January 2016, the FASB issued ASU 2016-01, “Financial Instruments – Overall (Subtopic 825-10): Recognition and measurement of Financial Assets and Financial Liabilities,” which requires that all equity investments to be measured at fair value with changes in the fair value recognized through net income (other than those accounted for under equity method of accounting or those that result in consolidation of the investee). The amendments in this update also require an entity to present separately in other comprehensive income the portion of the total change in the fair value of a liability resulting from a change in the instrument-specific credit risk when the entity has elected to measure the liability at fair value in accordance with the fair value option for financial instruments. In addition, the amendments in this update eliminate the requirement to disclose the fair value of financial instruments measured at amortized cost for entities that are not public business entities and the requirement to disclose the method(s) and significant assumptions used to estimate the fair value that is required to be disclosed for financial instruments measured at amortized cost on the balance sheet for public business entities. The amendment is effective for financial statements issued for fiscal years beginning after December 15, 2017. Early adoption is not permitted. The Company is currently evaluating the impact of this standard on its financial statements. In July 2015, the FASB issued ASU 2015-11, “Simplifying the Measurement of Inventory.” ASU 2015-11 clarifies that inventory should be held at the lower of cost or net realizable value. Net realizable value is defined as the estimated selling price, less the estimated costs to complete, dispose and transport such inventory. ASU 2015-11 will be effective for fiscal years and interim periods beginning after December 15, 2016. ASU 2015-11 is required to be applied prospectively and early adoption is permitted. The adoption of ASU 2015-11 is not expected to have a material impact on the Company’s financial position or results of operations. In August 2014, the FASB issued ASU 2014-15, “Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern” (“ASU 2014-15”). ASU 2014-15 is intended to define management’s responsibility to evaluate whether there is substantial doubt about an organization’s ability to continue as a going concern and to provide related footnote disclosures. The amendments in this ASU are effective for reporting periods beginning after December 15, 2016, with early adoption permitted. The Company is evaluating the impact the adoption of ASU 2014-15 will have on its financial statements. In May 2014, the FASB issued ASU 2014-09 regarding ASC Topic 606, “Revenue from Contracts with Customers”. The standard provides principles for recognizing revenue for the transfer of promised goods or services to customers with the consideration to which the entity expects to be entitled in exchange for those goods or services. In August 2015, the FASB issued ASU 2015-14, Revenue from Contracts with Customers: Deferral of the Effective Date, which deferred the effective date of the new revenue standard for periods beginning after December 15, 2017, with early adoption permitted. The Company is currently evaluating the effect that the updated standard will have on its financial statements.

Fixed Assets

Fixed Assets	6 Months Ended
	Dec. 31, 2015
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	Note 2 – Fixed Assets Fixed assets are recorded at cost and, once placed in service, are depreciated on the straight-line method over the estimated useful lives. Estimated As of December 31, As of June 30, Office equipment and furniture 3 - 5 $ 108,000 $ - Lab equipment 3 - 5 90,000 90,000 Leasehold improvements 3 18,000 - Manufacturing equipment 5 7,000 - Less accumulated depreciation and amortization (79,000) (60,000) Fixed assets, net $ 144,000 $ 30,000

In-Process Research and Develop

In-Process Research and Development	6 Months Ended
	Dec. 31, 2015
Research and Development [Abstract]
Research, Development, and Computer Software Disclosure [Text Block]	Note 3 – In-Process Research and Development In-process research and development (“IPRD”) relates to the Zertane product candidate. The $ 7,500,000

Patents

Patents	6 Months Ended
	Dec. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets Disclosure [Text Block]	Note 4 – Patents Costs of establishing patents, consisting of legal and filing fees paid to third parties, are expensed as incurred. The fair value of the Zertane patents, determined by an independent, third party appraisal to be $ 500,000 11 380,000 15 As of December 31, As of June 30, Patents $ 880,000 $ 880,000 Less accumulated armortization (287,000) (251,000) Patents, net $ 593,000 $ 629,000

Revenue Recognition

Revenue Recognition	6 Months Ended
	Dec. 31, 2015
Text Block [Abstract]
License Agreement [Text Block]	Note 5 – Revenue Recognition The $ 448,000 7,000 System. The $ 914,000 13,000 The license revenue of $ 21,000 43,000 500,000 250,000

Fair Value Considerations

Fair Value Considerations	6 Months Ended
	Dec. 31, 2015
Business Combinations [Abstract]
Fair Value Consideration [Text Block]	Note 6 – Fair Value Considerations Aytu’s financial instruments include cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities, convertible promissory notes and warrant derivative liability. The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate their fair value due to their short maturities. The fair value of the convertible notes is approximately the face value of the notes, $ 5,175,000 Authoritative guidance defines fair value as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the measurement date. The guidance establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of Aytu. Unobservable inputs are inputs that reflect Aytu’s assumptions of what market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy is broken down into three levels based on reliability of the inputs as follows: Level 1: Inputs that reflect unadjusted quoted prices in active markets that are accessible to Aytu for identical assets or liabilities; Level 2: Inputs include quoted prices for similar assets and liabilities in active or inactive markets or that are observable for the asset or liability either directly or indirectly; and Level 3: Unobservable inputs that are supported by little or no market activity. Aytu’s assets and liabilities which are measured at fair value are classified in their entirety based on the lowest level of input that is significant to their fair value measurement. Aytu’s policy is to recognize transfers in and/or out of fair value hierarchy as of the date in which the event or change in circumstances caused the transfer. Aytu has consistently applied the valuation techniques discussed below in all periods presented. Fair Value Measurements Using Level 1 Level 2 Level 3 Total December 31, 2015 LIABILITIES Warrant derivative liability $ - $ - $ 181,000 $ 181,000 The warrant derivative liability for the warrants was valued using the Monte Carlo valuation methodology because that model embodies all of the relevant assumptions that address the features underlying these instruments. December 31, 2015 At Issuance Warrants: Exercise price $ 0.98 $1.51 - $1.95 Volatility 75.0 % 75.0 % Equivalent term (years) 4.67 5.0 - 5.11 Risk-free interest rate 1.57% - 1.60 % 1.54% - 1.74 % Potential number of shares 126,000 - 215,000 139,000 - 224,000 Derivative Instruments Balance as of June 30, 2015 $ - Warrant issuances 103,000 Included in earnings 78,000 Balance as of December 31, 2015 $ 181,000

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Dec. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	Note 7 – Commitments and Contingencies Total Remaining 2017 2018 2019 2020 Thereafter Management fee $ 1,620,000 $ 180,000 $ 360,000 $ 360,000 $ 360,000 $ 360,000 $ - Primsol business 1,250,000 1,000,000 250,000 - - - - Manufacturing agreement 1,000,000 1,000,000 - - - - - Office Lease 385,000 68,000 142,000 145,000 30,000 - - Sponsored research agreement with related party 315,000 35,000 70,000 70,000 70,000 70,000 - $ 4,570,000 $ 2,283,000 $ 822,000 $ 575,000 $ 460,000 $ 430,000 $ - Management Fee In July 2015, Aytu entered into an agreement with Ampio whereby Aytu agreed to pay Ampio $ 30,000 Primsol Business In October 2015, Aytu entered into an agreement with FSC Laboratories, Inc. for the purchase of Primsol (see Note 1). Manufacturing Agreement In October 2015, Aytu entered into a Master Services Agreement with Biovest International, Inc. (“Biovest”). The agreement provides that Aytu may engage Biovest from time to time to provide services in accordance with mutually agreed upon project addendums and purchase orders. Aytu expects to use the agreement from time to time for manufacturing services, including without limitation, the manufacturing, processing, quality control testing, release or storage of its products for the ProstaScint product. Aytu is obligated to pay Biovest $ 1.0 Office Lease In June 2015, Aytu entered into a 37 2,900 112,000 37 8,500 318,000 Three Months Ended December 31, Six Months Ended December 31, 2015 2014 2015 2014 Rent expense $ 34,000 $ 22,000 $ 51,000 $ 40,000 Sponsored Research Agreement with Related Party Aytu entered into a Sponsored Research Agreement with Trauma Research LLC (“TRLLC”), a related party, in June 2013. Under the terms of the Sponsored Research Agreement, TRLLC agreed to work collaboratively in advancing the RedoxSYS System diagnostic platform through research and development efforts. The Sponsored Research Agreement may be terminated without cause by either party on 30

Convertible Promissory Notes

Convertible Promissory Notes	6 Months Ended
	Dec. 31, 2015
Debt Disclosure [Abstract]
Debt Disclosure [Text Block]	Note 8 – Convertible Promissory Notes Convertible Promissory Notes During July and August 2015, Aytu closed on note purchase agreements with institutional and high net worth individual investors for the purchase and sale of convertible promissory notes (“Notes”) with an aggregate principal amount of $ 5.2 401,000 103,000 The Notes are an unsecured obligation. Unless earlier converted, the Notes will mature 18 2 8 12 14 The 4 The Company did not give recognition to the registration rights arrangement as management did not believe at issuance that probable payment under the contingent escalation clause would be required, thus there was no impact on the initial measurement of the Notes. The Company satisfied the registration rights arrangement in October 2015 upon the effectiveness of a registration statement on Form S-1. 120 4.63 The Company determined that the conversion option is not required to be bifurcated and accounted for as an embedded derivative liability. There was no intrinsic value to the beneficial conversion feature as it was determined that the effective conversion price exceeded the commitment date valuation price. The Notes contain a purchase premium option in the event of a sale transaction by the Company as defined in the Notes. A holder of the Notes will be entitled to receive, at the holder’s option, (i) repayment of the Note balance plus the amount equal to 25 Placement agents for the offerings sold the institutional portion of the offering of the Notes. Aytu sold the balance of the Notes to individuals and entities with whom Aytu has an established relationship. For Notes sold by the placement agent, Aytu paid the placement agent 8 20,000 The warrants were recorded at fair value as long-term liabilities on the Balance Sheet (see Note 6). Upon Aytu’s adoption of ASU 2015-3, the costs associated with the Notes were recorded as a long–term liability and are presented in the Balance Sheet as a direct reduction of the carrying amount of the Notes on their inception date. As of December 31, 2015, the carrying value of the Notes was $ 4.9 253,000

Common Stock

Common Stock	6 Months Ended
	Dec. 31, 2015
Equity [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	Note 9 – Common Stock Capital Stock At December 31, 2015 and June 30, 2015, Aytu had 300 0.0001 50 0.0001

Equity Instruments

Equity Instruments	6 Months Ended
	Dec. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	Note 10 – Equity Instruments Options Prior to the Merger, Aytu had two approved stock option plans (Luoxis 2013 Stock Option Plan and Vyrix 2013 Stock Option Plan), pursuant to which Aytu had reserved a total of 1,718,828 The Luoxis options that were in the money and all outstanding Vyrix options issued under the respective 2013 Option Plans were accelerated and cancelled in connection with the Merger. Option holders received a cash payment per option share equal to the difference between the consideration payable per share of common stock pursuant to the Merger and the exercise price of the option; if the consideration paid to holders of common stock was less than the exercise price of such options, no amount was paid to the option holder in connection with the cancellation. The cash payment during the period ended June 30, 2015 was $ 27,000 422,000 189,000 The Luoxis options that were not paid out were terminated pursuant to the terms of the 2013 Luoxis Option Plan. The Company treated these options as pre-vesting forfeitures and $ 433,000 On June 1, 2015, Aytu’s stockholders approved the 2015 Stock Option and Incentive Plan (the “2015 Plan”), which provides for the award of stock options, stock appreciation rights, restricted stock and other equity awards for up to an aggregate of 10,000,000 Expected volatility 75.00 % Risk free interest rate 1.08% - 2.08 % Expected term (years) 3.0 - 7.0 Dividend yield 0 % Number of Weighted Weighted Average Outstanding June 30, 2015 - $ - Granted 3,695,000 $ 1.55 Exercised - $ - Forfeited/Cancelled - $ - Outstanding December 31, 2015 3,695,000 $ 1.55 9.80 Exercisable at December 31, 2015 1,120,000 $ 1.51 9.87 Available for grant at December 31, 2015 6,305,000 Stock-based compensation expense related to the fair value of stock options was included in the statements of operations as research and development expenses and selling, general and administrative expenses as set forth in the table below. Aytu determined the fair value as of the date of grant using the Black-Scholes option pricing model and expenses the fair value ratably over the vesting period. Three Months Ended December 31, Six Months Ended December 31, 2015 2014 2015 2014 Research and development expenses Stock options $ 20,000 $ 117,000 $ 25,000 $ 207,000 Selling, general and administrative expenses Stock options $ 163,000 $ 159,000 226,000 271,000 $ 183,000 $ 276,000 $ 251,000 $ 478,000 Unrecognized expense at December 31, 2015 $ 1,890,000 Weighted average remaining years to vest 3.16 Of the options that Aytu issued during the six months ended December 31, 2015, 1,440,000 1.3 Warrants Aytu issued warrants in conjunction with its 2013 private placement. Number of Weighted Weighted Average Outstanding June 30, 2015 102,613 $ 4.53 2.92 Outstanding December 31, 2015 (unaudited) 102,613 $ 4.53 2.41 Warrant Obligation related to the Convertible Promissory Notes Aytu has the obligation to issue warrants to the private placement agents for the 2015 convertible note financing as part of their fees for the financing. These warrants are classified as a derivative warrant liability due to the fact that the number of shares and exercise price have not been set as of December 31, 2015. The number of shares of Company stock that these warrants will convert into is equal to 8% of the gross number of shares of the Company stock issuable upon conversion of the Notes issued to investors introduced to the Company by the private placement agents pursuant to the private placement memorandum. The exercise price will be the lower of the lowest conversion price per share at which the Notes are converted into Company common stock or $ 4.63

Related Party Transactions

Related Party Transactions	6 Months Ended
	Dec. 31, 2015
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	Note 11 – Related Party Transactions Ampio Loan Agreement In November 2013, Vyrix entered into a loan agreement with Ampio. Pursuant to the loan agreement, Ampio agreed to lend Vyrix up to an aggregate amount of $ 3,000,000 500,000 1,600,000 3.11 3.32 4,000,000 In March 2014, Luoxis entered into a loan agreement with Ampio. Pursuant to the loan agreement, Ampio agreed to lend Luoxis $ 3,000,000 3,000,000 3.11 3.32 8,000,000 On April 16, 2015, Ampio received 4,761,787 10,000,000 8,000,000 4,000,000 Services Agreement The Company has entered into a service agreement with Ampio which is described in Note 7. Sponsored Research Agreement In June 2013, Luoxis entered into a sponsored research agreement with TRLLC, an entity controlled by Ampio’s director and Chief Scientific Officer, Dr. Bar-Or. The agreement, which was amended in January 2015 and provides for Luoxis (now Aytu) to pay $ 6,000 615,000 60.5 Convertible Promissory Notes The convertible promissory notes (see Note 8) include $ 275,000

Subsequent Events

Subsequent Events	6 Months Ended
	Dec. 31, 2015
Subsequent Events [Abstract]
Subsequent Events [Text Block]	Note 12 – Subsequent Events On January, 4, 2016, Ampio distributed a portion of its shares of common stock of Aytu to the Ampio shareholders on a pro rata basis. This transaction changed Ampio’s ownership from 81.5 8.6 On January 5, 2016, Aytu accelerated the vesting of 335,000 On January 20, 2016, Aytu entered into subscription agreements with Joshua R. Disbrow, Aytu’s Chief Executive Officer, and Jarrett T. Disbrow, Aytu’s Chief Operating Officer, pursuant to which each officer agreed to purchase 153,846 0.65 Per the convertible promissory note agreements, if Aytu sells equity securities at any time while the notes are outstanding in a financing transaction that is not a Qualified Financing, the holders of the convertible promissory notes have the option, but not the obligation, to convert the outstanding principal and accrued interest as of the as of the closing of such financings into a number of shares of Aytu capital stock in an amount equal to 120% of the number of such shares calculated by dividing the outstanding principal and accrued interest by the lesser of (a) the lowest cash price per share paid by purchasers of shares in such financing, or (b) $4.63. As a result of Aytu’s sale of common stock on January 20, 2016, the Company was obligated to provide notice to the above-referenced noteholders of such stock sales. In accordance with the convertible note terms, for a period of ten business days (which was extended to 15 business days by the Company, or February 11, 2016) following receipt of the notice, noteholders have the option to convert their entire balance (inclusive of accrued but unpaid interest) into a number of shares of Aytu common stock equal to 120 0.65 4.1

Business, Acquisition of Asse20

Business, Acquisition of Assets and Basis of Presentation (Policies)	6 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation These unaudited financial statements represent the financial statements of Aytu BioScience, Inc. (“Aytu” or “the Company”). These unaudited financial statements should be read in conjunction with Aytu’s Annual Report on Form 10-K for the year ended June 30, 2015, which included all disclosures required by generally accepted accounting principles (“GAAP”). In the opinion of management, these unaudited financial statements contain all adjustments necessary to present fairly the financial position of Aytu for the balance sheet and the results of operations and cash flows for the interim periods presented. The results of operations for the period ended December 31, 2015 are not necessarily indicative of expected operating results for the full year. The information presented throughout this report as of and for the period ended December 31, 2015 is unaudited. Aytu’s current business was formed through a reverse triangular merger (the “Merger”) in which Luoxis Diagnostics, Inc. (“Luoxis”) and Vyrix Pharmaceuticals, Inc. (“Vyrix”) merged into Rosewind Corporation in a multi-step merger on April 16, 2015. These historical financial statements prior to April 16, 2015 include the combined financial statements of Vyrix from its inception in November 2013, combined with the carve-out financial statements related to Vyrix assets acquired in the Merger (the “Vyrix Acquired Assets”) from March 23, 2011, the date its parent company, Ampio Pharmaceuticals, Inc. (“Ampio”), originally acquired the Vyrix Acquired Assets through its merger with DMI BioSciences, Inc. (“BioSciences”) and the financial statements of Luoxis from its inception in January 2013, combined with the carve-out financial statements related to Luoxis. The carve-out financial statements present the statements of financial position of Vyrix and Luoxis and the Vyrix Acquired Assets and the statements of operations and cash flows for purposes of presenting complete comparative stand-alone financial statements in accordance with Regulation S-X, Article 3, General Instructions to Financial Statements, and Staff Accounting Bulletin Topic 1-B1, Costs Reflected in Historical Financial Statements. Historically, financial statements have not been prepared for Vyrix and Luoxis, as they were not held in a separate legal entity. Although Vyrix and Luoxis have not been segregated as a separate legal entity, related revenues, direct costs and expenses, assets and liabilities have historically been segregated on Ampio’s books. In addition, the Company allocated corporate overhead costs based on a review of specific labor and other overhead expenses and a reasonable estimate of activities related to Vyrix and Luoxis. Allocated labor and other overhead totaled $ 264,000 253,000 ically been funded by Ampio. The historical carve-out financial statements may not be indicative of the future results of Vyrix and Luoxis as a stand-alone entity. The “Company” as referred to in the notes to these financial statements includes Vyrix and Luoxis, collectively. As of December 31, 2015, Ampio is the majority shareholder of 81.5 12.174
Business Combinations Policy [Policy Text Block]	In May 2015, Aytu entered into and closed on an asset purchase agreement with Jazz Pharmaceuticals, Inc. (the “Seller”). Pursuant to the agreement, Aytu purchased assets related to the Seller’s product known as ProstaScint® (capromab pendetide), including certain intellectual property and contracts, and the product approvals, inventory and work in progress (together, the “ProstaScint Business”), and assumed certain of the Seller’s liabilities, including those related to product approvals and the sale and marketing of ProstaScint. The purchase price consisted of the upfront payment of $ 1.0 500,000 227,000 8 2.5 664,000 2.4 Fair Tangible assets $ 727,000 Intangible assets 1,590,000 Goodwill 74,000 Total assets acquired $ 2,391,000 Included in the intangible assets is developed technology of $ 790,000 720,000 80,000 As of December 31, 2015 the contingent consideration had increased to $ 688,000 Business Combination—Primsol In October 2015, Aytu entered into and closed on an Asset Purchase Agreement with FSC Laboratories, Inc. (the “Seller”). Pursuant to the agreement, Aytu purchased assets related to the Seller’s product known as Primsol® (trimethoprim solution), including certain intellectual property and contracts, inventory, work in progress and all marketing and sales assets and materials related solely to Primsol (together, the “Primsol Business”), and assumed certain of the Seller’s liabilities, including those related to the sale and marketing of Primsol arising after the closing. Aytu paid $ 500,000 142,000 102,000 40,000 500,000 500,000 250,000 Fair Tangible assets $ 182,000 Intangible assets 1,470,000 Goodwill 147,000 Total assets acquired $ 1,799,000 Included in tangible assets is $ 102,000 80,000 520,000 810,000 140,000
New Accounting Pronouncements, Policy [Policy Text Block]	Adoption of Newly Issued Accounting Pronouncements In September 2015, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2015-16, “Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments,” which requires that an acquirer recognize adjustments to estimated amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined. The amendments require that the acquirer record, in the same period’s financial statements, the effect on earnings of changes in depreciation, amortization, or other income effects, if any, as a result of the change to the estimated amounts, calculated as if the accounting had been completed at the acquisition date. The amendments also require an entity to present separately on the face of the income statement or disclose in the notes the portion of the amount recorded in current-period earnings by line item that would have been recorded in previous reporting periods if the adjustment to the estimated amounts had been recognized as of the acquisition date. The amendment is effective for financial statements issued for fiscal years beginning after December 15, 2015 and early adoption is permitted. As of December 31, 2015, the Company has early adopted this standard. In April 2015, the FASB issued ASU 2015-03, “Interest-Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs” to simplify the presentation of debt issuance costs. The amendments in the update require that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct reduction of the carrying amount of the debt. Recognition and measurement of debt issuance costs were not affected by this amendment. In August 2015, FASB issued ASU 2015-15, “Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements — Amendments to SEC Paragraphs Pursuant to Staff Announcement at June 18, 2015 EITF Meeting” which clarified that the SEC would not object to an entity deferring and presenting debt issuance costs as an asset and subsequently amortizing the deferred debt issuance costs ratably over the term of the line-of-credit arrangement. The amendments are effective for financial statements issued for fiscal years beginning after December 15, 2015. As of December 31, 2015, the Company early adopted this standard and will record any debt issuance costs as a debt discount. There was no impact related to this adoption as the Company did not have any debt issuance costs previously. In November 2015, the FASB issued ASU No. 2015-17 regarding ASC Topic 470 "Income Taxes: Balance Sheet Classification of Deferred Taxes." The amendments in ASU 2015-17 eliminate the requirement to bifurcate deferred taxes between current and non-current on the balance sheet and requires that deferred tax liabilities and assets be classified as noncurrent on the balance sheet. The amendments for ASU-2015-17 can be applied retrospectively or prospectively and early adoption is permitted. Aytu early adopted ASU 2015-17 and there was no material impact on its financial statements. Recently Issued Accounting Pronouncements, Not Adopted as of December 31, 2015 In January 2016, the FASB issued ASU 2016-01, “Financial Instruments – Overall (Subtopic 825-10): Recognition and measurement of Financial Assets and Financial Liabilities,” which requires that all equity investments to be measured at fair value with changes in the fair value recognized through net income (other than those accounted for under equity method of accounting or those that result in consolidation of the investee). The amendments in this update also require an entity to present separately in other comprehensive income the portion of the total change in the fair value of a liability resulting from a change in the instrument-specific credit risk when the entity has elected to measure the liability at fair value in accordance with the fair value option for financial instruments. In addition, the amendments in this update eliminate the requirement to disclose the fair value of financial instruments measured at amortized cost for entities that are not public business entities and the requirement to disclose the method(s) and significant assumptions used to estimate the fair value that is required to be disclosed for financial instruments measured at amortized cost on the balance sheet for public business entities. The amendment is effective for financial statements issued for fiscal years beginning after December 15, 2017. Early adoption is not permitted. The Company is currently evaluating the impact of this standard on its financial statements. In July 2015, the FASB issued ASU 2015-11, “Simplifying the Measurement of Inventory.” ASU 2015-11 clarifies that inventory should be held at the lower of cost or net realizable value. Net realizable value is defined as the estimated selling price, less the estimated costs to complete, dispose and transport such inventory. ASU 2015-11 will be effective for fiscal years and interim periods beginning after December 15, 2016. ASU 2015-11 is required to be applied prospectively and early adoption is permitted. The adoption of ASU 2015-11 is not expected to have a material impact on the Company’s financial position or results of operations. In August 2014, the FASB issued ASU 2014-15, “Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern” (“ASU 2014-15”). ASU 2014-15 is intended to define management’s responsibility to evaluate whether there is substantial doubt about an organization’s ability to continue as a going concern and to provide related footnote disclosures. The amendments in this ASU are effective for reporting periods beginning after December 15, 2016, with early adoption permitted. The Company is evaluating the impact the adoption of ASU 2014-15 will have on its financial statements. In May 2014, the FASB issued ASU 2014-09 regarding ASC Topic 606, “Revenue from Contracts with Customers”. The standard provides principles for recognizing revenue for the transfer of promised goods or services to customers with the consideration to which the entity expects to be entitled in exchange for those goods or services. In August 2015, the FASB issued ASU 2015-14, Revenue from Contracts with Customers: Deferral of the Effective Date, which deferred the effective date of the new revenue standard for periods beginning after December 15, 2017, with early adoption permitted. The Company is currently evaluating the effect that the updated standard will have on its financial statements.

Business, Acquisition of Asse21

Business, Acquisition of Assets and Basis of Presentation (Tables)	6 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]	Fair Tangible assets $ 727,000 Intangible assets 1,590,000 Goodwill 74,000 Total assets acquired $ 2,391,000 The Company’s allocation on consideration transferred for Primsol as of the purchase date of October 5, 2015 is as follows: Fair Tangible assets $ 182,000 Intangible assets 1,470,000 Goodwill 147,000 Total assets acquired $ 1,799,000

Fixed Assets (Tables)

Fixed Assets (Tables)	6 Months Ended
	Dec. 31, 2015
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment [Table Text Block]	Estimated As of December 31, As of June 30, Office equipment and furniture 3 - 5 $ 108,000 $ - Lab equipment 3 - 5 90,000 90,000 Leasehold improvements 3 18,000 - Manufacturing equipment 5 7,000 - Less accumulated depreciation and amortization (79,000) (60,000) Fixed assets, net $ 144,000 $ 30,000

Patents (Tables)

Patents (Tables)	6 Months Ended
	Dec. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Finite-Lived Intangible Assets [Table Text Block]	Patents consist of the following: As of December 31, As of June 30, Patents $ 880,000 $ 880,000 Less accumulated armortization (287,000) (251,000) Patents, net $ 593,000 $ 629,000

Fair Value Considerations (Tabl

Fair Value Considerations (Tables)	6 Months Ended
	Dec. 31, 2015
Business Combinations [Abstract]
Financial Assets And Liabilities Not Measured At Fair Value On Recurring Basis [Table Text Block]	Fair Value Measurements Using Level 1 Level 2 Level 3 Total December 31, 2015 LIABILITIES Warrant derivative liability $ - $ - $ 181,000 $ 181,000
Fair Value Inputs, Liabilities, Quantitative Information [Table Text Block]	Significant assumptions in valuing the warrant derivative liability, based on estimates of the value of Aytu common stock and various factors regarding the warrants, were as follows as of December 31, 2015 and at issuance: December 31, 2015 At Issuance Warrants: Exercise price $ 0.98 $1.51 - $1.95 Volatility 75.0 % 75.0 % Equivalent term (years) 4.67 5.0 - 5.11 Risk-free interest rate 1.57% - 1.60 % 1.54% - 1.74 % Potential number of shares 126,000 - 215,000 139,000 - 224,000
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	The following table sets forth a reconciliation of changes in the fair value of financial liabilities classified as Level 3 in the fair valued hierarchy: Derivative Instruments Balance as of June 30, 2015 $ - Warrant issuances 103,000 Included in earnings 78,000 Balance as of December 31, 2015 $ 181,000

Commitments and Contingencies (

Commitments and Contingencies (Tables)	6 Months Ended
	Dec. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments And Contingencies Disclosure [Table Text Block]	Total Remaining 2017 2018 2019 2020 Thereafter Management fee $ 1,620,000 $ 180,000 $ 360,000 $ 360,000 $ 360,000 $ 360,000 $ - Primsol business 1,250,000 1,000,000 250,000 - - - - Manufacturing agreement 1,000,000 1,000,000 - - - - - Office Lease 385,000 68,000 142,000 145,000 30,000 - - Sponsored research agreement with related party 315,000 35,000 70,000 70,000 70,000 70,000 - $ 4,570,000 $ 2,283,000 $ 822,000 $ 575,000 $ 460,000 $ 430,000 $ -
Schedule of Rent Expense [Table Text Block]	Rent expense for the respective periods is as follows: Three Months Ended December 31, Six Months Ended December 31, 2015 2014 2015 2014 Rent expense $ 34,000 $ 22,000 $ 51,000 $ 40,000

Equity Instruments (Tables)

Equity Instruments (Tables)	6 Months Ended
	Dec. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	time of the grant for treasury securities of similar maturity. Aytu has computed the fair value of all options granted during the six months ended December 31, 2015 using the following assumptions: Expected volatility 75.00 % Risk free interest rate 1.08% - 2.08 % Expected term (years) 3.0 - 7.0 Dividend yield 0 %
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	Stock option activity is as follows: Number of Weighted Weighted Average Outstanding June 30, 2015 - $ - Granted 3,695,000 $ 1.55 Exercised - $ - Forfeited/Cancelled - $ - Outstanding December 31, 2015 3,695,000 $ 1.55 9.80 Exercisable at December 31, 2015 1,120,000 $ 1.51 9.87 Available for grant at December 31, 2015 6,305,000
Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block]	The following table summarizes stock-based compensation expense for the three and six months ended December 31, 2015 and for the stock-based compensation expense related to the Luoxis and Vyrix options for the three and six months ended December 31, 2014: Three Months Ended December 31, Six Months Ended December 31, 2015 2014 2015 2014 Research and development expenses Stock options $ 20,000 $ 117,000 $ 25,000 $ 207,000 Selling, general and administrative expenses Stock options $ 163,000 $ 159,000 226,000 271,000 $ 183,000 $ 276,000 $ 251,000 $ 478,000 Unrecognized expense at December 31, 2015 $ 1,890,000 Weighted average remaining years to vest 3.16
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	A summary of these warrants is as follows: Number of Weighted Weighted Average Outstanding June 30, 2015 102,613 $ 4.53 2.92 Outstanding December 31, 2015 (unaudited) 102,613 $ 4.53 2.41

Business, Acquisition of Asse27

Business, Acquisition of Assets and Basis of Presentation (Details) - USD ($)	Dec. 31, 2015	Oct. 05, 2015	Jun. 30, 2015	May. 31, 2015	May. 20, 2015
Business Acquisition [Line Items]
Goodwill	$ 221,000		$ 74,000
Prostascint Business [Member]
Business Acquisition [Line Items]
Tangible assets		$ 182,000			$ 727,000
Intangible assets		1,470,000			1,590,000
Goodwill		147,000			74,000
Total assets acquired		$ 1,799,000		$ 2,400,000	$ 2,391,000

Business, Acquisition of Asse28

Business, Acquisition of Assets and Basis of Presentation (Details Textual)	Jun. 08, 2015	Oct. 31, 2015USD ($)	May. 31, 2015USD ($)	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)	Oct. 05, 2015USD ($)	May. 20, 2015USD ($)
Business Acquisition [Line Items]
Other Labor-related Expenses				$ 264,000	$ 253,000
Sale of Stock, Percentage of Ownership after Transaction				81.50%
Stockholders' Equity, Reverse Stock Split				On June8, 2015, in connection with the reincorporation as a Delaware corporation, the Company effected a reverse stock split in which each common stock holder received one share of common stock for every 12.174 shares then outstanding (the Reverse Stock Split).
Stockholders' Equity Note, Stock Split, Conversion Ratio	12.174
Payments to Acquire Businesses, Gross				$ 540,000	$ 0
Developed Technology Rights [Member]
Business Acquisition [Line Items]
Amortization of Intangible Assets				520,000
Trade Names [Member]
Business Acquisition [Line Items]
Amortization of Intangible Assets				140,000
Customer Contracts [Member]
Business Acquisition [Line Items]
Amortization of Intangible Assets				810,000
Prostascint Business [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets, Total			$ 2,400,000			$ 1,799,000	$ 2,391,000
Payments to Acquire Businesses, Gross			1,000,000
Business Combination, Consideration Transferred, Liabilities Incurred			500,000	$ 227,000
Business Combination, Contingent Consideration Arrangements, Change in Range of Outcomes, Contingent Consideration, Liability, Reasons				Aytu also will pay 8% as contingent consideration on its net sales made after October31, 2017, payable up to a maximum aggregate payment of an additional $2.5 million.
Business Combination, Contingent Consideration Arrangements, Change in Range of Outcomes, Contingent Consideration, Liability, Value, High			$ 2,500,000
Business Combination Contingent Consideration Percentage			8.00%
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Asset			$ 664,000	$ 688,000
Jazz Pharmaceuticals Inc [Member] | Prosta Scint [Member] | Maximum [Member]
Business Acquisition [Line Items]
Finite-Lived Intangible Assets, Remaining Amortization Period				10 years
Jazz Pharmaceuticals Inc [Member] | Prosta Scint [Member] | Developed Technology Rights [Member]
Business Acquisition [Line Items]
Finite-Lived Intangible Assets, Gross				$ 790,000
Jazz Pharmaceuticals Inc [Member] | Prosta Scint [Member] | Trade Names [Member]
Business Acquisition [Line Items]
Finite-Lived Intangible Assets, Gross				80,000
Jazz Pharmaceuticals Inc [Member] | Prosta Scint [Member] | Customer Contracts [Member]
Business Acquisition [Line Items]
Finite-Lived Intangible Assets, Gross				720,000
Primsol Business [Member]
Business Acquisition [Line Items]
Payments to Acquire Businesses, Gross		$ 500,000
Business Combination, Consideration Transferred, Liabilities Incurred		142,000
Business Combination Consideration Transferred Inventory		102,000		102,000
Business Combination Consideration Transferred Product Inventory		40,000
Business Combination Consideration Transferred Work In Process Inventory				$ 80,000
Primsol Business [Member] | No Later Than March 31, 2016 [Member]
Business Acquisition [Line Items]
Business Combination, Consideration Transferred, Liabilities Incurred		500,000
Primsol Business [Member] | No Later Than June 30, 2016 [Member]
Business Acquisition [Line Items]
Business Combination, Consideration Transferred, Liabilities Incurred		500,000
Primsol Business [Member] | No Later Than September 30, 2016 [Member]
Business Acquisition [Line Items]
Business Combination, Consideration Transferred, Liabilities Incurred		$ 250,000

Fixed Assets (Details)

Fixed Assets (Details) - USD ($)	6 Months Ended
	Dec. 31, 2015	Jun. 30, 2015
Property, Plant and Equipment [Line Items]
Less accumulated depreciation and amortization	$ (79,000)	$ (60,000)
Fixed assets, net	143,826	29,706
Office equipment and furniture [Member]
Property, Plant and Equipment [Line Items]
Fixed assets, gross	$ 108,000	0
Office equipment and furniture [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	3 years
Office equipment and furniture [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	5 years
Lab equipment [Member]
Property, Plant and Equipment [Line Items]
Fixed assets, gross	$ 90,000	90,000
Lab equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	3 years
Lab equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	5 years
Leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Fixed assets, gross	$ 18,000	0
Estimated useful lives	3 years
Manufacturing equipment [Member]
Property, Plant and Equipment [Line Items]
Fixed assets, gross	$ 7,000	$ 0
Estimated useful lives	5 years

In-Process Research and Devel30

In-Process Research and Development (Details Textual)	Dec. 31, 2015USD ($)
Zertane Patents [Member]
Indefinite-lived Intangible Assets [Line Items]
Indefinite-Lived Intangible Assets (Excluding Goodwill)	$ 7,500,000

Patents (Details)

Patents (Details) - USD ($)	Dec. 31, 2015	Jun. 30, 2015
Indefinite-lived Intangible Assets [Line Items]
Patents, net	$ 593,382	$ 628,776
Patents [Member]
Indefinite-lived Intangible Assets [Line Items]
Patents	880,000	880,000
Less accumulated armortization	(287,000)	(251,000)
Patents, net	$ 593,000	$ 629,000

Patents (Details Textual)

Patents (Details Textual)	6 Months Ended
	Dec. 31, 2015USD ($)
Zertane Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	$ 500,000
Finite-Lived Intangible Assets, Remaining Amortization Period	11 years
ORP [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	$ 380,000
Finite-Lived Intangible Assets, Remaining Amortization Period	15 years

Revenue Recognition (Details Te

Revenue Recognition (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2015	Dec. 31, 2014
Revenue Recognition [Line Items]
Revenue, Net, Total	$ 448,000	$ 7,000	$ 914,000	$ 13,000
License and Maintenance Revenue			21,000	$ 43,000
KOREA, REPUBLIC OF | Korean Pharmaceutical Company [Member]
Revenue Recognition [Line Items]
Deferred Revenue	500,000		$ 500,000
Deferred Revenue Recognition Period			10 years	10 years
CANADA | Canadian Based Supplier [Member]
Revenue Recognition [Line Items]
Deferred Revenue	$ 250,000		$ 250,000
Deferred Revenue Recognition Period			7 years	7 years

Fair Value Considerations (Deta

Fair Value Considerations (Details) - USD ($)	Dec. 31, 2015	Aug. 31, 2015	Jun. 30, 2015
LIABILITIES
Warrant derivative liability	$ 180,969	$ 103,000	$ 0
Fair Value, Inputs, Level 1 [Member]
LIABILITIES
Warrant derivative liability	0
Fair Value, Inputs, Level 2 [Member]
LIABILITIES
Warrant derivative liability	0
Fair Value, Inputs, Level 3 [Member]
LIABILITIES
Warrant derivative liability	$ 181,000

Fair Value Considerations (De35

Fair Value Considerations (Details 1)	6 Months Ended
	Dec. 31, 2015$ / sharesshares
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Equivalent term (years)	5 years
Warrant [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Exercise price | $ / shares	$ 0.98
Volatility	75.00%
Equivalent term (years)	4 years 8 months 1 day
Warrant [Member] | Maximum [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Risk-free interest rate	1.60%
Potential number of shares	215,000
Warrant [Member] | Minimum [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Risk-free interest rate	1.57%
Potential number of shares	126,000
Issuance Date [Member] | Warrant [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Volatility	75.00%
Issuance Date [Member] | Warrant [Member] | Maximum [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Exercise price | $ / shares	$ 1.95
Equivalent term (years)	5 years 1 month 10 days
Risk-free interest rate	1.74%
Potential number of shares	224,000
Issuance Date [Member] | Warrant [Member] | Minimum [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Exercise price | $ / shares	$ 1.51
Equivalent term (years)	5 years
Risk-free interest rate	1.54%
Potential number of shares	139,000

Fair Value Considerations (De36

Fair Value Considerations (Details 2) - Fair Value, Inputs, Level 3 [Member]	6 Months Ended
	Dec. 31, 2015USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Balance as of June 30, 2015	$ 0
Warrant issuances	103,000
Included in earnings	78,000
Balance as of December 31, 2015	$ 181,000

Fair Value Considerations (De37

Fair Value Considerations (Details Textual) - USD ($)	Dec. 31, 2015	Aug. 31, 2015
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Debt Instrument, Face Amount	$ 5,175,000	$ 5,200,000

Commitments and Contingencies38

Commitments and Contingencies (Details) - USD ($)	Dec. 31, 2015	Oct. 31, 2015
Unrecorded Unconditional Purchase Obligation [Line Items]
Total	$ 4,570,000
2,016	2,283,000
2,017	822,000
2,018	575,000
2,019	460,000
2,020	430,000
Thereafter	0
Management Fees [Member]
Unrecorded Unconditional Purchase Obligation [Line Items]
Total	1,620,000
2,016	180,000
2,017	360,000
2,018	360,000
2,019	360,000
2,020	360,000
Thereafter	0
Primsol Business [Member]
Unrecorded Unconditional Purchase Obligation [Line Items]
Total	1,250,000
2,016	1,000,000
2,017	250,000
2,018	0
2,019	0
2,020	0
Thereafter	0
Manufacturing Agreement [Member]
Unrecorded Unconditional Purchase Obligation [Line Items]
Total	1,000,000	$ 1,000,000
2,016	1,000,000
2,017	0
2,018	0
2,019	0
2,020	0
Thereafter	0
Office Lease [Member]
Unrecorded Unconditional Purchase Obligation [Line Items]
Total	385,000
2,016	68,000
2,017	142,000
2,018	145,000
2,019	30,000
2,020	0
Thereafter	0
Sponsored research agreement with related party [Member]
Unrecorded Unconditional Purchase Obligation [Line Items]
Total	315,000
2,016	35,000
2,017	70,000
2,018	70,000
2,019	70,000
2,020	70,000
Thereafter	$ 0

Commitments and Contingencies39

Commitments and Contingencies (Details 1) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2015	Dec. 31, 2014
Commitments And Contingencies Rent Expense [Line Items]
Rent expense	$ 34,000	$ 22,000	$ 51,000	$ 40,000

Commitments and Contingencies40

Commitments and Contingencies (Details Textual) - USD ($)	1 Months Ended			6 Months Ended
	Sep. 30, 2015	Jul. 31, 2015	Jun. 30, 2015	Dec. 31, 2015	Oct. 31, 2015
Unrecorded Unconditional Purchase Obligation [Line Items]
Management Fee Payable Per Month		$ 30,000
Contractual Obligation, Total				$ 4,570,000
COLORADO [Member]
Unrecorded Unconditional Purchase Obligation [Line Items]
Operating Leases Monthly Base Rent Initial Year	$ 8,500
Lessee Leasing Arrangements, Operating Leases, Term of Contract	37 months
Operating Leases, Rent Expense	$ 318,000
NORTH CAROLINA [Member]
Unrecorded Unconditional Purchase Obligation [Line Items]
Operating Leases Monthly Base Rent Initial Year			$ 2,900
Lessee Leasing Arrangements, Operating Leases, Term of Contract			37 months
Operating Leases, Rent Expense			$ 112,000
Sponsored research agreement with related party [Member]
Unrecorded Unconditional Purchase Obligation [Line Items]
Contractual Obligation, Total				$ 315,000
Agreement Termination Notice Period				30 days
Manufacturing Agreement [Member]
Unrecorded Unconditional Purchase Obligation [Line Items]
Contractual Obligation, Total				$ 1,000,000	$ 1,000,000

Convertible Promissory Notes (D

Convertible Promissory Notes (Details Textual) - USD ($)	6 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Aug. 31, 2015	Jun. 30, 2015
Debt Conversion [Line Items]
Debt Instrument, Face Amount	$ 5,175,000		$ 5,200,000
Unamortized Debt Issuance Expense	253,000		401,000
Derivative Liability, Noncurrent	180,969		$ 103,000	$ 0
Proceeds from Convertible Debt	$ 5,175,000	$ 0
Class Of Warrant Term	5 years
Debt Issuance Cost	$ 20,000
Placement Agents Cash Fee Percentage	8.00%
Convertible Notes Payable, Noncurrent	$ 4,921,552			$ 0
Convertible Promissory Notes [Member]
Debt Conversion [Line Items]
Debt Instrument Interest Rate For Extension Period1	2.00%
Debt Instrument, Term	18 months
Debt Instrument, Interest Rate, Stated Percentage Rate Range, Minimum	8.00%
Debt Instrument, Interest Rate, Stated Percentage Rate Range, Maximum	12.00%
Debt Instrument, Interest Rate, Increase (Decrease)	14.00%
Debt Instrument Interest Additional Interest Above Rate	4.00%
Convertible Notes Equal To Percentage Of Common Stock	120.00%
Debt Instrument Conversion Share Price	$ 4.63
Debt Instrument, Convertible, Terms of Conversion Feature	The Notes are convertible at any time at the noteholder’s discretion into that number of shares of Aytu common stock equal to 120% of the number of shares of common stock calculated by dividing the then outstanding principal and accrued interest by $4.63. A holder of Notes will be obligated to convert on the terms of Aytu’s next public offering of its stock resulting in gross proceeds of at least $5,000,000 (excluding indebtedness converted in such financing) prior to the maturity date of the Notes (a “Qualified Financing”). The principal and accrued interest under the Notes will automatically convert into a number of shares of such equity securities of the Company sold in the Qualified Financing equal to 120% of the principal and accrued interest under such Note divided by the lesser of (i) the lowest price paid by an investor in the Qualified Financing or (ii) $4.63. In the event that Aytu sells equity securities to investors at any time while the Notes are outstanding in a financing transaction that is not a Qualified Financing, then the noteholders will have the option to convert in whole the outstanding principal and accrued interest as of the closing of such financing into a number of shares of Aytu capital stock in an amount equal to 120% of the number of such shares calculated by dividing the outstanding principal and accrued interest by the lesser of (i) the lowest cash price per share paid by purchasers of shares in such financing, or (ii) $4.63.
Debt Purchase Price Percent Of Principal Amount	25.00%
Debt Issuance Cost	$ 0
Convertible Promissory Notes [Member] | Minimum [Member]
Debt Conversion [Line Items]
Proceeds from Convertible Debt	$ 5,000,000
Convertible Promissory Notes [Member] | Promissory Notes Payable One [Member]
Debt Conversion [Line Items]
Debt Instrument, Maturity Date	Jan. 22, 2017
Convertible Promissory Notes [Member] | Promissory Notes Payable Two [Member]
Debt Conversion [Line Items]
Debt Instrument, Maturity Date	Feb. 11, 2017
Convertible Promissory Notes [Member] | Promissory Notes Payable Three [Member]
Debt Conversion [Line Items]
Debt Instrument, Maturity Date	Feb. 28, 2017

Common Stock (Details Textual)

Common Stock (Details Textual) - $ / shares	Dec. 31, 2015	Jun. 30, 2015
Common Stock [Line Items]
Common Stock, Shares Authorized	300,000,000	300,000,000
Common Stock, Par or Stated Value Per Share	$ 0.0001	$ 0.0001
Preferred Stock, Shares Authorized	50,000,000	50,000,000
Preferred Stock, Par or Stated Value Per Share	$ 0.0001	$ 0.0001

Equity Instruments (Details)

Equity Instruments (Details) - Luoxis Diagnostics [Member]	6 Months Ended
	Dec. 31, 2015
Assumptions Used To Determine Fair Value Options [Line Items]
Expected volatility	75.00%
Risk free interest rate, Minimum	1.08%
Risk free interest rate, Maximum	2.08%
Dividend yield	0.00%
Minimum [Member]
Assumptions Used To Determine Fair Value Options [Line Items]
Expected term (years)	3 years
Maximum [Member]
Assumptions Used To Determine Fair Value Options [Line Items]
Expected term (years)	7 years

Equity Instruments (Details 1)

Equity Instruments (Details 1) - Luoxis Diagnostics [Member]	6 Months Ended
	Dec. 31, 2015$ / sharesshares
Number of Options
Number of Options, Beginning Balance	0
Number of Options, Granted	3,695,000
Number of Options, Exercised	0
Number of Options, Forfeited/Cancelled	0
Number of Options, Ending Balance	3,695,000
Exercisable at September 30, 2015	1,120,000
Available for grant at September 30, 2015	6,305,000
Weighted Average Exercise Price
Weighted Average Exercise Price, Beginning Balance | $ / shares	$ 0
Weighted Average Exercise Price, Granted | $ / shares	1.55
Weighted Average Exercise Price, Exercised | $ / shares	0
Weighted Average Exercise Price, Forfeited/Cancelled | $ / shares	0
Weighted Average Exercise Price, Ending Balance | $ / shares	1.55
Weighted average exercise price, Exercisable at September 30, 2015 | $ / shares	$ 1.51
Weighted Average Remaining Contractual Life
Weighted Average Remaining Contractual Life, Outstanding (in years)	9 years 9 months 18 days
Weighted Average Remaining Contractual Life, Excercisable (in years)	9 years 10 months 13 days

Equity Instruments (Details 2)

Equity Instruments (Details 2) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Jun. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense	$ 183,000	$ 276,000	$ 251,000	$ 478,000
Unrecognized expense at December 31, 2015	$ 1,890,000
Weighted average remaining years to vest (in years)	3 years 1 month 28 days
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense					$ 27,000
Research and Development Expense [Member] | Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense	$ 20,000	117,000	25,000	207,000
General and Administrative Expense [Member] | Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense	$ 163,000	$ 159,000	$ 226,000	$ 271,000

Equity Instruments (Details 3)

Equity Instruments (Details 3) - $ / shares	6 Months Ended	12 Months Ended
	Dec. 31, 2015	Jun. 30, 2015
Number of Warrants Outstanding
Number of Warrants Outstanding, Beginning Balance	102,613
Number of Warrants Outstanding, Ending Balance	102,613	102,613
Warrants, Weighted Average Exercise Price
Weighted Average Exercise Price, Outstanding Beginning Balance	$ 4.53
Weighted Average Exercise Price, Outstanding Ending Balance	$ 4.53	$ 4.53
Weighted Average Remaining Contractual Life
Weighted Average Remaining Contractual Life, Warrants Outstanding (in years)	2 years 4 months 28 days	2 years 11 months 1 day

Equity Instruments (Details Tex

Equity Instruments (Details Textual) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Jun. 30, 2015	Jun. 02, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common Stock, Capital Shares Reserved for Future Issuance	1,718,828,000,000		1,718,828,000,000
Allocated Share-based Compensation Expense	$ 183,000	$ 276,000	$ 251,000	$ 478,000
Conversion of Stock, Description			The number of shares of Company stock that these warrants will convert into is equal to 8% of the gross number of shares of the Company stock issuable upon conversion of the Notes issued to investors introduced to the Company by the private placement agents pursuant to the private placement memorandum. The exercise price will be the lower of the lowest conversion price per share at which the Notes are converted into Company common stock or $4.63. The warrants have a term of five years from August 31, 2015 (see Note 6).
Fair Value Assumptions, Expected Term			5 years
Ampio Board And Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures, Total			$ 1,440,000
Ampio [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense			$ 1,300,000
Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Debt Instrument, Convertible, Conversion Price	$ 4.63		$ 4.63
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense					$ 27,000
Luoxis 2013 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total					422,000
Reversal Of Allocated Share Based Compensation Expense			$ 433,000
2015 Stock Option and Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Deferred Compensation Arrangement with Individual, Shares Authorized for Issuance						10,000,000
Vyrix 2013 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total					$ 189,000

Related Party Transactions (Det

Related Party Transactions (Details Textual) - USD ($)	1 Months Ended				3 Months Ended	12 Months Ended
	Apr. 16, 2015	Mar. 30, 2014	Nov. 30, 2013	Jun. 30, 2013	Sep. 30, 2015	Jun. 30, 2014	Dec. 31, 2015	Aug. 31, 2015	Jun. 30, 2015	Mar. 31, 2014
Related Party Transaction [Line Items]
Common Stock, Shares, Issued							14,259,693		14,259,681
Debt Instrument, Face Amount							$ 5,175,000	$ 5,200,000
Ampio [Member]
Related Party Transaction [Line Items]
Common Stock, Shares, Issued	4,761,787
Ampio [Member] | Senior Management [Member]
Related Party Transaction [Line Items]
Convertible Notes Payable							$ 275,000
Ampio [Member] | Second Installment [Member] | Scenario, Plan [Member]
Related Party Transaction [Line Items]
Property Subject to or Available for Operating Lease, Net, Total				$ 615,000
Ampio [Member] | Second Installment [Member] | After Amendment [Member] | Scenario, Plan [Member]
Related Party Transaction [Line Items]
Operating Lease Monthly Rental Payment				$ 6,000
Ampio [Member] | First Installment [Member] | Scenario, Plan [Member]
Related Party Transaction [Line Items]
Prepaid Expenses Amortization Period					60 months 15 days
Ampio [Member] | Ampio Loan Agreement [Member]
Related Party Transaction [Line Items]
Cash Advances For Short Term Loans			$ 500,000
Long-term Line of Credit			$ 3,000,000							$ 3,000,000
Debt Instrument, Term		1 year	1 year
Ampio [Member] | Ampio Loan Agreement [Member] | Vyrix Pharmaceuticals Inc [Member]
Related Party Transaction [Line Items]
Line of Credit Facility, Remaining Borrowing Capacity	$ 4,000,000					$ 1,600,000
Debt Instrument, Interest Rate, Stated Percentage Rate Range, Minimum						3.11%
Debt Instrument, Interest Rate, Stated Percentage Rate Range, Maximum						3.32%
Ampio [Member] | Ampio Loan Agreement [Member] | Luoxis Diagnostics [Member]
Related Party Transaction [Line Items]
Line of Credit Facility, Remaining Borrowing Capacity	8,000,000					$ 3,000,000
Debt Instrument, Interest Rate, Stated Percentage Rate Range, Minimum						3.11%
Debt Instrument, Interest Rate, Stated Percentage Rate Range, Maximum						3.32%
Ampio [Member] | Promissory Note [Member]
Related Party Transaction [Line Items]
Debt Instrument, Face Amount	10,000,000
Ampio [Member] | Promissory Note [Member] | Vyrix Pharmaceuticals Inc [Member]
Related Party Transaction [Line Items]
Debt Instrument, Decrease, Forgiveness	4,000,000
Ampio [Member] | Promissory Note [Member] | Luoxis Diagnostics [Member]
Related Party Transaction [Line Items]
Debt Instrument, Decrease, Forgiveness	$ 8,000,000

Subsequent Events (Details Text

Subsequent Events (Details Textual) - USD ($)	Jan. 05, 2016	Jan. 20, 2016	Feb. 05, 2016	Jan. 04, 2016	Dec. 31, 2015	Aug. 31, 2015
Subsequent Event [Line Items]
Debt Instrument, Face Amount					$ 5,175,000	$ 5,200,000
Subsequent Event [Member]
Subsequent Event [Line Items]
Debt Instrument, Face Amount			$ 4,100,000
Subsequent Event [Member] | Subscription Arrangement [Member]
Subsequent Event [Line Items]
Stock Issued During Period, Shares, New Issues		153,846
Share Price		$ 0.65
Proceeds from Issuance of Common Stock		$ 200,000
Subsequent Event [Member] | Convertible Promissory Notes [Member]
Subsequent Event [Line Items]
Debt Conversion, Description		principal and accrued interest as of the closing of such financings into a number of shares of Aytu capital stock in an amount equal to 120% of the number of such shares calculated by dividing the outstanding principal and accrued interest by the lesser of (a) the lowest cash price per share paid by purchasers of shares in such financing, or (b) $4.63.
Debt Instrument, Convertible, Conversion Price		$ 0.65
Convertible Notes Equal To Percentage Of Common Stock		120.00%
Subsequent Event [Member] | Ampio [Member]
Subsequent Event [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares	335,000
Subsequent Event [Member] | Ampio [Member] | Maximum [Member]
Subsequent Event [Line Items]
Percentage Of Ownership Interest Held by New Shareholder				81.50%
Subsequent Event [Member] | Ampio [Member] | Minimum [Member]
Subsequent Event [Line Items]
Percentage Of Ownership Interest Held by New Shareholder				8.60%